Familial adenomatous polyposis medical therapy

Familial adenomatous polyposis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Familial adenomatous polyposis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT Scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Familial adenomatous polyposis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Familial adenomatous polyposis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Familial adenomatous polyposis medical therapy
CDC on Familial adenomatous polyposis medical therapy
Familial adenomatous polyposis medical therapy in the news
Blogs on Familial adenomatous polyposis medical therapy
Directions to Hospitals Treating Familial adenomatous polyposis
Risk calculators and risk factors for Familial adenomatous polyposis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

Various medications are being investigated for slowing malignant degeneration of polyps, most prominently the non-steroidal anti-inflammatory drugs (NSAIDs). The NSAIDS have been shown to significantly decrease the number of polyps but does not usually alter management since there are still too many polyps to be followed and treated endoscopically.